⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ouro Medicines and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Ouro Medicines
↗South San Francisco, USA
Ouro Medicines is a biotechnology company dedicated to developing 'immune reset' therapeutics for patients suffering from chronic immune-mediated diseases. The company focuses on leveraging T cell engagers to target B cell-mediated diseases, aiming to achieve durable remissions without the need for ongoing immunosuppression.
Founded in 2024 and based in South San Francisco, the company has quickly established itself in the field of autoimmune disease research. It was acquired by Gilead Sciences in March 2026, marking a significant milestone in its rapid development trajectory.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Series A
Total Raised:$120M
Investors:New Enterprise Associates, TPG, Norwest Venture Partners, Monograph Capital, GSK, UPMC Enterprise
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Bispecific T cell engagers (TCE), Monoclonal antibodies
Active Trials:1
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Gilead Sciences
Acquired By:Gilead Sciences (2026-03-01)
Key Partnerships:ConneXion (Kangnuoya) - Licensing of OM336, GSK - Founding partnership
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Kite Pharma, Sana Biotechnology
LINKS
Website:ouromeds.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ouro Medicines. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.